We read with great interest the population-based cohort study by Abrahami D et al ,1 in which they found that the use of proton pump inhibitors (PPIs) was not associated with an increased risk of inflammatory bowel disease (IBD). However, the assessment of causality in observational studies is often challenging due to the presence of multiple confounding factors. The existence of a causal relationship between PPIs and IBD remains unclear at present. Mendelian randomisation (MR) is a method of generating more reliable evidence using exposure-related genetic variants to assess causality, limiting the bias caused by confounders.2 Therefore, we used a two-sample MR analysis to investigate the association between the use of PPIs and IBD including Crohn’s disease (CD) and ulcerative colitis (UC). For this study, different cohort data sources were used for exposure and outcome to avoid sample overlap (online supplemental material). We used summary statistics from the medication use case-control genome-wide association studies conducted among UK Biobank study participants to generate genetic instruments for …

中文翻译：

---

质子泵抑制剂和炎症性肠病的风险：一项孟德尔随机化研究


我们饶有兴趣地阅读了 Abrahami D 等人 1 的基于人群的队列研究，其中他们发现质子泵抑制剂 （PPI） 的使用与炎症性肠病 （IBD） 的风险增加无关。然而，由于存在多种混杂因素，观察性研究中对因果关系的评估通常具有挑战性。目前尚不清楚 PPI 和 IBD 之间是否存在因果关系。孟德尔随机化 （MR） 是一种使用与暴露相关的遗传变异来评估因果关系来生成更可靠证据的方法，从而限制了混杂因素引起的偏倚。因此，我们使用双样本 MR 分析来研究 PPI 的使用与 IBD 之间的关联，包括克罗恩病 （CD） 和溃疡性结肠炎 （UC）。在这项研究中，使用不同的队列数据源进行暴露和结局，以避免样本重叠（在线补充材料）。我们使用了在英国生物样本库研究参与者中进行的药物使用病例对照全基因组关联研究的汇总统计数据来生成遗传仪器......